12-2018

Gene Therapy Reimbursement Models – A Stakeholder Assessment

Aaron Bholé  
*Thomas Jefferson University, aaron.bhole@jefferson.edu*

Matthew Luminais, MSc  
*Militia Hill Ventures*

B. A. Sillah, MD, MBA  
*Militia Hill Ventures*

**Let us know how access to this document benefits you**

Follow this and additional works at: [https://jdc.jefferson.edu/si_phr_2021_phase1](https://jdc.jefferson.edu/si_phr_2021_phase1)

🔗 Part of the [Medical Education Commons](https://jdc.jefferson.edu/meded), and the [Public Health Commons](https://jdc.jefferson.edu/meded)

---

**Recommended Citation**

Bholé, Aaron; Luminais, MSc, Matthew; and Sillah, MD, MBA, B. A., "Gene Therapy Reimbursement Models – A Stakeholder Assessment" (2018). SKMC JeffMD Scholarly Inquiry, Phase 1, Project 1.

---

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s [Center for Teaching and Learning (CTL)](http://ctl.jefferson.edu). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).
Gene Therapy Reimbursement Models – A Stakeholder Assessment

Introduction: The first one-time curative gene therapy was approved in December 2017 with a list price of $850,000, and there is a historic increase in gene therapy clinical trials with 89 having reached phase III as of May 2018. Gene therapy’s high upfront cost will challenge the traditional reimbursement models which are well suited for common, chronic conditions.

Objective: This stakeholder assessment surveys groups to identify existing opinions and generate insights regarding gene therapies and their reimbursement models.

Methods: A 12 question survey was sent to 200 stakeholders with the list generated from author’s contacts. Stakeholder groups targeted were providers, payers, biotech/pharma, finance, consulting, government, patients &/or disease advocacy groups, scientists, and think tanks/academia. Findings from the survey are intended to be directional and hypothesis-generating instead of statistically representative.

Results: 26 individuals responded to the survey, but based upon self-reported familiarity with gene therapies five respondents were excluded.

The average favorability of gene therapy model adoption in the next 5 years (n=21) was as follows: outcomes based payments (7.33), annuity payments (5.52), upfront payments (4.62), modified upfront payments (5.61).

The average favorability of gene therapy model adoption in the next 15 years (n=21) was as follows: outcomes based payments (7.76), annuity payments (5.57), upfront payments (4.29), modified upfront payments (5.52).
Conclusion: Stakeholders surveyed responded with the highest favorability for outcomes based contracts and expressed general positive responses regarding efficacy/safety profiles. The main limitation for this survey is the sample size (n=21) and stakeholder make up with only 2 payers/insurers. Next steps include collecting more payer responses.

(250 word limit)